MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Caladrius Biosciences EBITDA 2011-2025 | CLBS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Caladrius Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.2 M | -25.5 M | -57.5 M | -29 M | -19.1 M | -20 M | -16.8 M | -27.2 M | -28.6 M | -48.9 M | -55.6 M | -35.2 M | -28.8 M | -26.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -16.8 M | -57.5 M | -31.5 M |
Quarterly EBITDA Caladrius Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.37 M | -4.82 M | -5.8 M | - | -5.29 M | -5.48 M | -6.56 M | - | -5.95 M | -6.86 M | -6.8 M | - | -37.7 M | -6.71 M | -6.61 M | - | -6.92 M | -7.15 M | -8.07 M | - | -5.3 M | -4.26 M | -4.04 M | - | -5.02 M | -5.31 M | -4.58 M | - | -3.56 M | -4.1 M | -5.07 M | - | -5.85 M | -7.52 M | -5.78 M | - | -5.38 M | -7.15 M | -10.3 M | - | -8.49 M | -24.4 M | -17.5 M | - | -14.7 M | -11.4 M | -13.1 M | - | -8.12 M | -7.34 M | -8.28 M | - | -6.93 M | -6.04 M | -7.16 M | - | -6.01 M | -9.12 M | -4.87 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.56 M | -37.7 M | -8.04 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
9.9 B | $ 223.01 | -0.99 % | $ 395 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-76.7 M | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-141 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
AlloVir
ALVR
|
-200 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-130 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
1.19 M | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
234 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
-81.2 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-396 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
673 M | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
BioVie
BIVI
|
-17.8 M | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
-2.45 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-620 M | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
-56.6 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
-66.2 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
8.39 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
107 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Cerus Corporation
CERS
|
-12.4 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Celldex Therapeutics
CLDX
|
-192 M | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Cellectar Biosciences
CLRB
|
-38.8 M | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Clovis Oncology
CLVS
|
-217 M | - | -7.23 % | $ 13 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 0.29 | -5.01 % | $ 631 M | Israel |
 |
Cortexyme
CRTX
|
-34.3 M | - | -1.05 % | $ 67.1 M | USA |
 |
Benitec Biopharma
BNTC
|
-9.77 M | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-527 M | $ 60.38 | 0.11 % | $ 6.76 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Deciphera Pharmaceuticals
DCPH
|
-209 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-679 M | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
505 K | $ 10.89 | -0.09 % | $ 1.42 B | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-34.3 M | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | USA |